N1540
NO-1886
别名:
Diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate, Ibrolipim, OPF 009
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H20BrN2O4P
化学文摘社编号:
分子量:
451.25
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
KPRTURMJVWXURQ-UHFFFAOYSA-N
SMILES string
CCOP(=O)(Cc1ccc(cc1)C(=O)Nc2ccc(Br)cc2C#N)OCC
InChI
1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
assay
≥98% (HPLC)
form
powder
color
off-white to pale yellow
solubility
DMSO: ≥20 mg/mL
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Lipoprotein lipase activator. Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. Long-term administration of NO-1886 protects against the development of experimental atherosclerosis in animals.
Packaging
Packaged under nitrogen
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Xin Ma et al.
Cardiovascular drugs and therapy, 23(3), 199-206 (2009-02-21)
The Niemann-Pick C1 (NPC1) protein regulates the transport of cholesterol from late endosomes/lysosomes to other compartments responsible for maintaining intracellular cholesterol homeostasis. Liver X receptors (LXRs) operate as cholesterol sensors which may protect from cholesterol overload by increasing the amount
Zong-Bao Wang et al.
The Journal of pharmacy and pharmacology, 64(2), 293-301 (2012-01-10)
The aim of the study was to elucidate the possible role and mechanism of NO-1886 (ibrolipim, a lipoprotein lipase activator) in ameliorating insulin resistance induced by high palmitate. HepG2 cells were cultured in RPMI 1640 medium and were treated with
Seiichiro Kano et al.
Metabolism: clinical and experimental, 55(2), 151-158 (2006-01-21)
The synthetic compound NO-1886 (ibrolipim, [4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester, CAS 133208-93-2) is a lipoprotein lipase (LPL)-promoting agent that decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels, and prevents fat accumulation in high fat-fed rats. However, the effect of NO-1886 on
Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al.
Michael H Davidson
Cardiovascular drugs and therapy, 23(3), 187-188 (2009-05-13)
Masataka Kusunoki et al.
European journal of pharmacology, 668(1-2), 337-339 (2011-07-16)
It is known that postheparin plasma lipoprotein lipase (LPL) activity correlates with serum high density lipoprotein cholesterol (HDL-C) levels in humans and animals. Furthermore, LPL has been reported to cause enlargement of HDL particle size in vitro. However, these effects
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持